Standout Papers
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer (2018)
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study (2016)
Immediate Impact
21 by Nobel laureates 16 from Science/Nature 77 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
2024 Standout
Towards targeting the breast cancer immune microenvironment
2024 Standout
Works of Marcella Fassò being referenced
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
2018 Standout
Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Marcella Fassò | 2070 | 1297 | 712 | 42 | 2.8k | |
| Geoffrey D. Young | 2252 | 1374 | 501 | 28 | 3.1k | |
| Carol O’Hear | 2025 | 699 | 664 | 58 | 2.4k | |
| Simon J. Dovedi | 1951 | 1342 | 563 | 60 | 2.7k | |
| Denise Frosina | 2240 | 1849 | 1007 | 49 | 4.1k | |
| William L. Redmond | 1837 | 2269 | 489 | 78 | 3.2k | |
| Elizabeth Stankevich | 2383 | 1288 | 657 | 39 | 2.8k | |
| Cristina Cruz | 2695 | 1216 | 648 | 36 | 3.6k | |
| Maria Jure–Kunkel | 2267 | 1961 | 370 | 42 | 3.0k | |
| Carlos Alfaro | 2200 | 2087 | 394 | 54 | 3.6k | |
| Dan Laheru | 1417 | 653 | 345 | 68 | 2.0k |
All Works
Loading papers...